Netscientific logo

NSCI - Netscientific Share Price

3.5p -0.1  -2.8%

Last Trade - 21/02/20

Sector
Healthcare
Size
Micro Cap
Market Cap £2.75m
Enterprise Value £-216k
Revenue £317k
Position in Universe 1729th / 1838
Bullish
Bearish
Unlock NSCI Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

NSCI Revenue Unlock NSCI Revenue

Net Income

NSCI Net Income Unlock NSCI Revenue

Normalised EPS

NSCI Normalised EPS Unlock NSCI Revenue

PE Ratio Range

NSCI PE Ratio Range Unlock NSCI Revenue

Dividend Yield Range

NSCI Dividend Yield Range Unlock NSCI Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
NSCI EPS Forecasts Unlock NSCI Revenue
Profile Summary

NetScientific plc is a transatlantic healthcare technology company. The Company develops and manages early/mid-stage healthcare technology companies sourced from strategic partnerships and relationships in the United States and Europe with a primary focus on diagnostics, digital health and therapeutics. The Company is engaged in the development of intellectual property. Its portfolio consists of WANDA Health, an analytics company that uses machine learning to derive a personalized risk score for Congestive Heart Failure patients; Glucosense, a provider of a non-invasive glucose monitoring wearable device; Vortex Biosciences, which is engaged in circulating tumor cell identification, selection and analysis for disease monitoring and personalized therapeutic prescribing; Glycotest, which provides non-invasive blood tests for liver cancers and fibrosis-cirrhosis, and ProAxsis, which is engaged in respiratory disease diagnosis and treatment monitoring.

Directors
Last Annual December 31st, 2018
Last Interim June 30th, 2019
Incorporated April 12, 2012
Public Since September 16, 2013
No. of Shareholders: n/a
No. of Employees: 30,000
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange London Stock Exchange (AIM)
Shares in Issue 78,561,866
Free Float (0.0%)
Eligible for
ISAs
SIPPs
NSCI Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for NSCI
Upcoming Events for NSCI
Similar to NSCI
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.